Posted in | Nanomedicine

Celator Broadens Application of CombiPlex Platform and CPX-351 for AML Treatment

Published on July 18, 2014 at 6:20 AM

Celator Pharmaceuticals, Inc., a pharmaceutical company developing new and more effective therapies to treat cancer, today will present updates on its lead candidate CPX-351 and CombiPlex® technology platform at its Analyst Day meeting for analysts and investors.

"We are very excited to announce that we are broadening the application of the CombiPlex platform and expect to advance the technology to include molecularly targeted therapies in 2015," said Scott Jackson, Chief Executive Officer of Celator Pharmaceuticals. "We also are broadening the potential use of CPX-351 primarily through investigator-initiated studies, and exploring its use in special AML populations, such as patients who are unfit for standard induction therapy, as well as other hematological malignancies such as myelodysplasia. Regarding our Phase 3 pivotal study of CPX-351 in patients with secondary AML, we expect to complete enrollment in the fourth quarter of 2014, which would keep us on track to report initial data in the second quarter of 2015."

At our Analyst Day program, members of the Celator management team and invited speakers will provide reviews of the company's technology platform and development programs, with an in-depth focus on CPX-351. CPX-351 is a 5:1 synergistic ratio of cytarabine:daunorubicin, co-encapsulated in a nano-scale liposome, based on Celator's CombiPlex technology platform. The CombiPlex approach allows patients elevated exposure to synergistic drug ratios with selective delivery to tumor cells for a prolonged period of time. Celator is currently enrolling patients in a Phase 3 study comparing CPX-351 versus the conventional cytarabine and daunorubicin treatment regimen (commonly referred to as 7+3) as first-line therapy in older patients with high-risk (secondary) AML.

Source: http://www.celatorpharma.com

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Submit